PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Taiwanese Journal of Obstetrics and Gynecology0 citationsOpen Access

Impact of niraparib on reducing the platelet count in patients with ovarian cancer

View Full Paper
MMMika MizunoMNMai NakazonoMFMika Fukuda

Key Points

  • Thrombocytopenia is a significant adverse event affecting niraparib continuation in patients with ovarian cancer.
  • The study reported that monitoring platelet counts is crucial for managing treatment with niraparib.
  • Real-world data was utilized to assess the impact of niraparib on platelet levels.
  • Further larger-scale studies are necessary to validate these findings and improve patient outcomes.

Abstract

Our real-world data reaffirmed that thrombocytopenia is a significant adverse event that affects the continuation of NIRA and requires careful monitoring. Adjusting the start time to ensure an adequate baseline PLT may help mitigate this risk, but larger-scale studies are needed to validate these findings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mizuno et al. (2026) studied this question.

synapsesocial.com/papers/69a75bf0c6e9836116a242echttps://doi.org/10.1016/j.tjog.2025.04.024
Ask AI
Helpful
Bookmark
Share
View Full Paper